GLP-1 and diabetes. Glucagon-like peptide-1 (GLP-1) is a 30- or 31-amino-acid-long peptide hormone deriving from tissue-specific posttranslational processing of the proglucagon peptide.
GLP-1 medications naturally help with appetite suppression, but pairing them with caloric restriction such as reducing intake by 500750 calories per day can accelerate weight loss.
Originally developed for type 2 diabetes management, GLP1 analogues such as semaglutide and tirzepatide have shown notable reductions in body weight when used at higher doses.
Mounjaro (tirzepatide) is the first and only, once-weekly approved single-molecule GIP and GLP-1 receptor agonist that helps lower A1C for adults with type 2 diabetes.
GLP-1 medications are changing how we approach weight management but theyre just one part of a bigger, more compassionate picture. In this episode, we explore why shame and blame have never worked in treating obesity and how shared decision-making can lead to better outcomes.
Introduction: Glucagon-like peptide-1 (GLP-1) analogues could induce clinically significant weight loss in obese patients with type 2 diabetes mellitus (T2DM). Beinaglutide is a GLP-1 analogue that is fully homologous to human GLP-1. This study aims to investigate the clinical efficacy of...
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. NEJM 2016.
The importance of exercise for glycemic control in type 2 diabetes.
:max_bytes(150000):strip_icc()/HDC-GettyImages-2195485788-299e147644524b339a084114355dff83.jpg "Image result for GLP-1 analogs for type 2 diabetes management with caloric restriction")
